Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Two SARS-CoV-2 mRNA vaccines were approved to prevent COVID-19 infection, with reported vaccine efficacy of 95%. Liver transplant (LT) recipients are at risk for lower vaccine immunogenicity and were not included in the registration trials. We assessed vaccine immunogenicity and safety in this special population.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research